L
Lara M. Simpson
Researcher at University of Texas at Austin
Publications - 51
Citations - 9044
Lara M. Simpson is an academic researcher from University of Texas at Austin. The author has contributed to research in topics: Heart failure & Myocardial infarction. The author has an hindex of 23, co-authored 49 publications receiving 8328 citations. Previous affiliations of Lara M. Simpson include University of Texas Health Science Center at Houston & Veterans Health Administration.
Papers
More filters
Journal ArticleDOI
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
Curt D. Furberg,Jackson T. Wright,Barry R. Davis,Jeffrey A. Cutler,Michael H. Alderman,Henry R. Black,William C. Cushman,Richard H. Grimm,L. Julian Haywood,Frans H. H. Leenen,Suzanne Oparil,Jeffrey L. Probstfield,Paul K. Whelton,Chuke Nwachuku,David Gordon,Michael A. Proschan,Paula Einhom,Charles E. Ford,Linda B. Piller,I. Kay Dunn,David C. Goff,Sara L. Pressel,Judy Bettencourt,Barbara DeLeon,Lara M. Simpson,Joe Blanton,Therese S. Geraci,Sandra M. Walsh,Christine Nelson,Mahboob Rahman,Anne Juratovac,Robert Pospisil,Lillian Carroll,Sheila Sullivan,Jeanne Russo,Gail Barone,Rudy Christian,Sharon Feldman,Tracy Lucente,David A. Calhoun,Kim Jenkins,Peggy McDowell,Janice Johnson,Connie Kingry,Juan Alzate,Karen L. Margolis,Leslie Ann Holland-Klemme,Brenda Jaeger,Jeff D. Williamson,Gail T. Louis,Pamela Ragusa,Angela Williard,R. L Sue Ferguson,Joanna Tanner,John H. Eckfeldt,Richard S. Crow,John Pelosi +56 more
TL;DR: Thiazide-type diuretics are superior in preventing 1 or more major forms of CVD and are less expensive and should be preferred for first-step antihypertensive therapy.
Journal ArticleDOI
Effect of Transendocardial Delivery of Autologous Bone Marrow Mononuclear Cells on Functional Capacity, Left Ventricular Function, and Perfusion in Chronic Heart Failure: The FOCUS-CCTRN Trial
Emerson C. Perin,James T. Willerson,Carl J. Pepine,Timothy D. Henry,Stephen G. Ellis,David Zhao,Guilherme V. Silva,Dejian Lai,James D. Thomas,Marvin W. Kronenberg,A. Daniel Martin,R. David Anderson,Jay H. Traverse,Marc S. Penn,Saif Anwaruddin,Antonis K. Hatzopoulos,Adrian P. Gee,Doris A. Taylor,Christopher R. Cogle,Deirdre Smith,Lynette Westbrook,James Chen,Eileen M. Handberg,Rachel E. Olson,Carrie Geither,Sherry Bowman,Judy Francescon,Sarah Baraniuk,Linda B. Piller,Lara M. Simpson,Catalin Loghin,David Aguilar,Sara Richman,Claudia Zierold,Judy Bettencourt,Shelly L. Sayre,Rachel W. Vojvodic,Sonia I. Skarlatos,David Gordon,Ray F. Ebert,Minjung Kwak,Lemuel A. Moyé,Robert D. Simari +42 more
TL;DR: Among patients with chronic ischemic heart failure, transendocardial injection of autologous BMCs compared with placebo did not improve LVESV, maximal oxygen consumption, or reversibility on SPECT.
Journal ArticleDOI
Reduction of Stroke Incidence After Myocardial Infarction With Pravastatin The Cholesterol and Recurrent Events (CARE) Study
Jonathan F. Plehn,Barry R. Davis,Frank M. Sacks,Jean L. Rouleau,Marc A. Pfeffer,Victoria Bernstein,T. Edward Cuddy,Lemuel A. Moyé,Linda B. Piller,John D. Rutherford,Lara M. Simpson,Eugene Braunwald +11 more
TL;DR: In this article, the authors used prospectively defined criteria to assess the incidence of stroke, a prespecified secondary end point, and transient ischemic attack (TIA) over a median 5-year follow-up period.
Journal ArticleDOI
Effect of Intracoronary Delivery of Autologous Bone Marrow Mononuclear Cells 2 to 3 Weeks Following Acute Myocardial Infarction on Left Ventricular Function The LateTIME Randomized Trial
Jay H. Traverse,Timothy D. Henry,Stephen G. Ellis,Carl J. Pepine,James T. Willerson,David Zhao,John R. Forder,Barry J. Byrne,Antonis K. Hatzopoulos,Marc S. Penn,Emerson C. Perin,Kenneth W. Baran,Jeffrey W. Chambers,Charles R. Lambert,Ganesh Raveendran,Daniel I. Simon,Douglas E. Vaughan,Lara M. Simpson,Adrian P. Gee,Doris A. Taylor,Christopher R. Cogle,James D. Thomas,Guilherme V. Silva,Beth C. Jorgenson,Rachel E. Olson,Sherry Bowman,Judy Francescon,Carrie Geither,Eileen M. Handberg,Deirdre Smith,Sarah Baraniuk,Linda B. Piller,Catalin Loghin,David Aguilar,Sara Richman,Claudia Zierold,Judy Bettencourt,Shelly L. Sayre,Rachel W. Vojvodic,Sonia I. Skarlatos,David Gordon,Ray F. Ebert,Minjung Kwak,Lemuel A. Moyé,Robert D. Simari +44 more
TL;DR: Among patients with MI and LV dysfunction following reperfusion with PCI, intracoronary infusion of autologous BMCs vs intrac oronary placebo infusion, 2 to 3 weeks after PCI, did not improve global or regional function at 6 months.
Journal ArticleDOI
Effect of the Use and Timing of Bone Marrow Mononuclear Cell Delivery on Left Ventricular Function After Acute Myocardial Infarction: The TIME Randomized Trial
Jay H. Traverse,Timothy D. Henry,Carl J. Pepine,James T. Willerson,David Zhao,Stephen G. Ellis,John R. Forder,R. David Anderson,Antonis K. Hatzopoulos,Marc S. Penn,Emerson C. Perin,Jeffrey W. Chambers,Kenneth W. Baran,Ganesh Raveendran,Charles R. Lambert,Amir Lerman,Daniel I. Simon,Douglas E. Vaughan,Dejian Lai,Adrian P. Gee,Doris A. Taylor,Christopher R. Cogle,James D. Thomas,Rachel E. Olson,Sherry Bowman,Judy Francescon,Carrie Geither,Eileen M. Handberg,Casey Kappenman,Lynette Westbrook,Linda B. Piller,Lara M. Simpson,Sarah Baraniuk,Catalin Loghin,David Aguilar,Sara Richman,Claudia Zierold,Daniel B. Spoon,Judy Bettencourt,Shelly L. Sayre,Rachel W. Vojvodic,Sonia I. Skarlatos,David Gordon,Ray F. Ebert,Minjung Kwak,Lemuel A. Moyé,Robert D. Simari +46 more
TL;DR: Among patients with STEMI treated with primary PCI, the administration of intracoronary BMCs at either 3 days or 7 days after the event had no significant effect on recovery of global or regional left ventricular function compared with placebo.